Format

Send to

Choose Destination
Cell. 2016 Jun 16;165(7):1560. doi: 10.1016/j.cell.2016.05.080.

A BH3 Mimetic for Killing Cancer Cells.

Author information

1
Department of Immunology, St. Jude Children's Research Institute, Memphis, TN 38105, USA. Electronic address: douglas.green@stjude.org.

Abstract

Venetoclax is a BH3 mimetic approved for treating chronic lymphocytic leukemia. Cancer cells are resistant to apoptosis but "primed for death" by elevated BCL-2, which binds to pro-apoptotic proteins and holds them in check. Venetoclax releases this antagonism and is the first approved drug to target a protein-protein interaction.

PMID:
27315468
DOI:
10.1016/j.cell.2016.05.080
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center